Refine by
Applications
- Freeze-Dried Hemostatic for Patients
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Liposomes - Hollow Nanospheres for Gene Therapy
- Liposomes - Hollow Nanospheres for Cancer Therapy
- Liposomes - Hollow Nanospheres for Ocular Drug Delivery
- Liposomes - Hollow Nanospheres for Brain Drug Delivery
- Liposomes - Hollow Nanospheres for Vaccines
- Liposomes - Hollow Nanospheres for Immunomodulating Response
- Liposomes - Hollow Nanospheres for Tissue Engineering
Drug Target Equipment & Supplies
171 equipment items found
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. ...
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for [18F]-choline (FCH). ...
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for 6-fluoro-[18F]-L-DOPA, a DOPA analog. Neurology, ...
by:TAE Life Sciences (TLS) based inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a boron delivery ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI ...
Manufactured by:Systasy Bioscience GmbH based inMunich, GERMANY
The proprietary splitSENSOR technology is a highly sensitive,flexible and easy-to-use reporter assay system to monitor various cellular events in living cells, including the activity of drug targets. Various cellular events, such as regulated protein-protein interactions, can be robustly and quantitatively measured both at the membrane and in the cytosol of the ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Agonist refers to substances that activate a specific target protein. It can easily be viewed as the opposite of inhibitor. Until now, Deargen's drug-target interaction (DTI) was predicted based on the binding affinity between the substance and the target protein, which causes barrier to distinguish between the inhibition and ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug ...
Manufactured by:G3T Therapeutics based inMidlothian, VIRGINIA (USA)
All drugs targeting cardiovascular disease currently on the market work by lowering cholesterol levels. G3T identified and genetically validated an entirely novel biological mechanism and potential drug target that treats both cardiovascular disease, as well as non-alcoholic fatty liver disease. ...
Manufactured by:Inoviem Scientific SAS based inIllkirch-Graffenstaden, FRANCE
Identify the mode of action of your compound with NPOT® technology; NPOT technology is a unique heterogeneous assembly method for conducting extensive identification of all proteins (together with their native structure) involved in drug-target ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Genome editing is efficient, precise and scalable. CRISPR/Cas9 genome editing can make permanent, precisely targeted changes in patients’ chromosomes and repair the underlying genetic mutation, whereas more traditional gene therapy typically involves introducing a non-permanent copy of a gene into patients’ cells. These attributes of CRISPR/Cas9 provide a significant therapeutic edge ...
Manufactured by:Isarna Therapeutics GmbH based inMunich, GERMANY
Because TGF-β is chronically elevated in many diseases, including ophthalmic and fibrotic diseases and cancer, and involved in their pathophysiology, it is an extremely versatile drug target throughout the body. ...
Distributed by:MoBiTec GmbH based inGoettingen, GERMANY
COVID-19 Research: Antiviral Drug Target ? The COVID-19 pandemic is caused by infection of SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2, a positive-sense single-stranded RNA virus. The RNA dependent RNA polymerase (RdRp) is a key drug target for this deadly virus. ...
Manufactured by:Evox Therapeutics Limited based inOxford, UNITED KINGDOM
Targeted delivery of nanoparticles is an area that has been intensively researched. Targeted drug delivery has a role to play in the delivery of many if not all drugs, but targeted delivery systems are critical for the delivery of nucleic acid-based agents such as siRNA and CRISPR-Cas ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, ...
Manufactured by:OPKO Health, Inc. based inMiami, FLORIDA (USA)
This strategy is unique and contrasts with established approaches which down-regulate protein production. This platform can lead to the discovery of new drugs to target relevant genes that regulate the optimal production of endogenous functional proteins. One of the leading applications of our AntagoNAT technology is OPK88001 which is designed for the treatment ...
Manufactured by:Kala Pharmaceuticals, Inc. based inArlington, MASSACHUSETTS (USA)
AMPPLIFY Drug Delivery Technology is designed to enhance penetration through the mucus barrier and deliver increased concentration of drug to the target ocular tissue. AMPPLIFY Drug Delivery Technology has been shown to improve delivery of loteprednol etabonate compared to traditional suspension eyedrops without ...